refers to widespread skin rash followed by high fever, observed in infants and caused due to viral infection. Rashes usually occur on arms, legs and trunk in the form of pink to red spots. These rashes may or may not be itchy in nature and sometimes the patient may suffer from fever, fatigue, loss of appetite, pains, headache and irritability. Treatment is required in cases of severe symptoms such as diarrhea, vomiting, severe abdominal pain, seizures, stiff neck, red eyes and sputum with pus or blood. However, certain medications can be taken for low fever, headaches and pains and others. Globally, increasing research activities for development of novel therapeutics against viral exanthema symptoms, rise in susceptibility of infants towards these infections due to weak immune system and increasing government support are the prime growth drivers of exanthema market. In addition, increase in cases of exanthema in emerging economies such as China, India, Brazil and others, will create new opportunities for exanthema market. However, higher cost of the research, negligence towards diagnosing the symptoms and lack of standardization are the key restraints for exanthema market.
This report identifies the global exanthema market
size in for the year 2014-2016 and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape and other key aspects with respect to global exanthema market.
Geographically, North America dominated the exanthema market and Asia Pacific is projected to have fastest growth, owing to rapidly increasing awareness levels, modernizing healthcare infrastructure and favourable government support in this region. Chloroamphenicol sodium succinate, tazarotene and threolone are some of the drugs in the investigational phases for treatment of exanthema.This report segments exanthema market on the basis of type and regional market as follows:
This report identifies all the major companies operating in the exanthema market. Some of the major companies’ profiles in detail are as follows:
- Exanthema Market, By Product: Rubeola, Rubella, Erythema Infectiosum and Roseola Infantum
- This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets in each of the region
- Manus Aktteva Biopharma LLP
- Teva Pharmaceutical Industries Ltd.
- CIRON Drugs & Pharmaceuticals Pvt. Ltd.
- Iol Chemicals And Pharmaceuticals Limited
- Reckitt Benckiser Group plc